NovoLog 70/30 (Insulin) for Diabetes

Overview
NovoLog 70/30 is a prescription drug approved by the Food and Drug Administration (FDA) to treat diabetes. NovoLog 70/30 is also referred to by its drug name, 70% insulin aspart protamine and 30% insulin aspart (rDNA origin).

NovoLog 70/30 is a combination of short-acting and intermediate-acting human insulin analogs. An insulin analog is a synthetic substance very similar to human insulin. Insulin analogs are designed to affect the body more predictably than human insulin does.

How do I take it?
Prescribing information states that NovoLog 70/30 should be administered via a subcutaneous injection. Your doctor will explain when and where you should inject NovoLog 70/30 and how to measure your dosage. NovoLog 70/30 is usually prescribed to be taken twice daily.

NovoLog 70/30 comes as a liquid in vials and pre-filled pens.

Side effects
The FDA-approved label for NovoLog 70/30 lists common side effects including hypoglycemia (low blood glucose), swelling of the extremities, lipodystrophy (fat degeneration), and minor redness or irritation at injection sites.

Rare but serious side effects listed for NovoLog 70/30 can include a systemic allergic reaction and heart failure.